Skip to main content
Natera logo
NTRA.NASDAQ
Natera
Healthcare · Diagnostics & Research

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide.

HQ: United StatesListed: United States

Profile & Fundamentals

Review the profile, reported financial history, AI financial assessment, dividends, splits, and dated events for Natera.

Profile & Fundamentals

Natera Profile & Fundamentals

Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.

Interactive annual & quarterly chartsAI financial reviewsReported source tables
Explore this pageJump to a Profile & Fundamentals section

Company and Market Context

Company Profile & Ownership

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in Januar

NTRA.NASDAQ

Company profile record

Natera Inc

Common Stock · Healthcare · Diagnostics & Research

Official website

Company

Company / asset
Natera Inc
Security type
Common Stock
Sector
Healthcare
Industry
Diagnostics & Research
HQ
🇺🇸 United States
Head office
13011 McCallen Pass, Austin, TX, United States, 78753

Leadership & scale

Chief executive
Mr. Steven Leonard Chapman
CEO year born
1979
Full-time employees
6.1K
Fiscal year end
December
IPO date
2015-07-02

Fundamentals snapshot

Updated 2026-07-27
Market Cap
USD 37.9B
P/E
--
Revenue (Q1 26)
USD 696.6M
Profit (Q1 26)
USD -85.1M
Dividend Yield
--
Revenue (FY 25)
USD 2.3B
Shares in public float
139.1M
Insider ownership
2.98%

Reporting & identifiers

Symbol
NTRA.NASDAQ
Listing
🇺🇸 United States | Dividend Tax: 30%
Ticker Currency
USD
Income Statement Currency
USD
Balance Sheet Currency
USD
Cash Flow Currency
USD
EPS Currency
USD
Contract Type
SPOT
ISIN
US6323071042
Asset ID
equity_9bcb5738-6092-5a90-83b0-28f2be8172b2

Ownership

Shares Outstanding

Latest: 141.5M | Max: 141.5M | Min: 4.3M

Shares Outstanding
178.3M133.7M89.1M44.6M0.00
'13
'15
'17
'19
'21
'23
'25
'26

Complete Research Workspace

Unlock the complete Profile & Fundamentals

Sign in to verify your access, or upgrade to the Base plan to open every chart, financial statement, event, and source table.